Novartis AG (0QLR) Share Forecast & Price Target

12 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0QLR Analyst Ratings

Hold

4 Buy

9 Hold

1 Sell

Based on 14 analysts giving stock ratings to

Novartis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0QLR Stock 12 Month Forecast

Average Price Target

CHF125.93

▲(0.90% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Novartis AG in the last 3 months. The average price target is CHF125.93 with a high forecast of CHF150.00 and a low forecast of CHF105.00. The average price target represents a 0.90% change from the last price of CHF124.80.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"95":"CHF95","109":"CHF109","123":"CHF123","137":"CHF137","151":"CHF151"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":150,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF150.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125.92857142857143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF125.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF105.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[95,109,123,137,151],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.325,120.76153846153846,123.19807692307693,125.63461538461539,128.07115384615383,130.5076923076923,132.94423076923078,135.38076923076923,137.81730769230768,140.25384615384615,142.69038461538463,145.12692307692308,147.56346153846152,{"y":150,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.325,118.90989010989011,119.49478021978022,120.07967032967034,120.66456043956045,121.24945054945056,121.83434065934067,122.41923076923077,123.00412087912088,123.58901098901099,124.1739010989011,124.75879120879121,125.34368131868132,{"y":125.92857142857143,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.325,117.3,116.275,115.25,114.22500000000001,113.2,112.175,111.15,110.125,109.1,108.075,107.05,106.025,{"y":105,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":100.269,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.478,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.327,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.779,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.173,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.541,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.575,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.551,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.625,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.021,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.325,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF150.00

Average Price TargetCHF125.93

Lowest Price TargetCHF105.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Justin Smith

Bernstein

CHF132.84→CHF127

Hold

1.76%

Upside

Assigned

10/29/26

Bernstein Reaffirms Their Hold Rating on Novartis AG (NOVN)

Richard Vosser

J.P. Morgan

CHF135→CHF145

Buy

16.19%

Upside

Reiterated

10/29/26

Novartis AG (NOVN) Gets a Buy from J.P. Morgan

Matthew Weston

UBS

CHF116→CHF130

Hold

4.17%

Upside

Reiterated

10/28/26

UBS Reaffirms Their Hold Rating on Novartis AG (NOVN)

James Gordon CFA

Barclays

CHF125

Hold

0.16%

Upside

Reiterated

10/28/26

Novartis AG (NOVN) Gets a Hold from Barclays

Thibault Boutherin

Morgan Stanley

CHF130→CHF135

Buy

8.17%

Upside

Reiterated

10/28/26

Novartis Upgraded to ‘Safe Haven’ Buy as Analyst Lifts Price Target to SFr 135 on Margin Upside and Mid-Term Growth

Graham Parry

Citi

CHF135

Buy

8.17%

Upside

Reiterated

10/28/26

Citi Reaffirms Their Buy Rating on Novartis AG (NOVN)

James Quigley

Goldman Sachs

CHF113

Sell

-9.46%

Downside

Reiterated

10/28/26

Novartis AG (NOVN) Gets a Sell from Goldman Sachs

Emmanuel Papadakis

Deutsche Bank

CHF120

Hold

-3.85%

Downside

Reiterated

10/27/26

Deutsche Bank Sticks to Its Hold Rating for Novartis AG (NOVN)

Sachin Jain

Bank of America Securities

CHF150

Buy

20.19%

Upside

Reiterated

10/27/26

Novartis: Buy Rating Reaffirmed on Earnings Beat, Improved Profitability and Underappreciated Growth; Price Target Unchanged at $150

Michael Leuchten

Jefferies

CHF110

Hold

-11.86%

Downside

Reiterated

10/27/26

Novartis AG (NOVN) Receives a Hold from Jefferies

Trung Huynh

RBC Capital

CHF120→CHF130

Hold

4.17%

Upside

Reiterated

10/26/26

Novartis AG (NOVN) Receives a Hold from RBC Capital

Kerry Holford

Berenberg Bank

CHF105

Hold

-15.87%

Downside

Reiterated

10/05/26

Novartis AG (NOVN) Receives a Hold from Berenberg Bank

Rajesh Kumar

HSBC

CHF110

Hold

-11.86%

Downside

Upgraded

09/09/26

Novartis upgraded to Hold from Reduce at HSBCNovartis upgraded to Hold from Reduce at HSBC

Unknown Analyst

Bank Vontobel

Not Ranked

Bank Vontobel

CHF130→CHF128

Hold

2.56%

Upside

Reiterated

09/07/26

Bank Vontobel Reaffirms Their Hold Rating on Novartis AG (NOVN)

Shelby Tucker

TD Cowen

CHF138

Hold

10.58%

Upside

Reiterated

07/27/26

Novartis: Solid Fundamentals but Balanced Risk-Reward Justify Hold Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Justin Smith

Bernstein

CHF132.84→CHF127

Hold

1.76%

Upside

Assigned

10/29/26

Bernstein Reaffirms Their Hold Rating on Novartis AG (NOVN)

Richard Vosser

J.P. Morgan

CHF135→CHF145

Buy

16.19%

Upside

Reiterated

10/29/26

Novartis AG (NOVN) Gets a Buy from J.P. Morgan

Matthew Weston

UBS

CHF116→CHF130

Hold

4.17%

Upside

Reiterated

10/28/26

UBS Reaffirms Their Hold Rating on Novartis AG (NOVN)

James Gordon CFA

Barclays

CHF125

Hold

0.16%

Upside

Reiterated

10/28/26

Novartis AG (NOVN) Gets a Hold from Barclays

Thibault Boutherin

Morgan Stanley

CHF130→CHF135

Buy

8.17%

Upside

Reiterated

10/28/26

Novartis Upgraded to ‘Safe Haven’ Buy as Analyst Lifts Price Target to SFr 135 on Margin Upside and Mid-Term Growth

Graham Parry

Citi

CHF135

Buy

8.17%

Upside

Reiterated

10/28/26

Citi Reaffirms Their Buy Rating on Novartis AG (NOVN)

James Quigley

Goldman Sachs

CHF113

Sell

-9.46%

Downside

Reiterated

10/28/26

Novartis AG (NOVN) Gets a Sell from Goldman Sachs

Emmanuel Papadakis

Deutsche Bank

CHF120

Hold

-3.85%

Downside

Reiterated

10/27/26

Deutsche Bank Sticks to Its Hold Rating for Novartis AG (NOVN)

Sachin Jain

Bank of America Securities

CHF150

Buy

20.19%

Upside

Reiterated

10/27/26

Novartis: Buy Rating Reaffirmed on Earnings Beat, Improved Profitability and Underappreciated Growth; Price Target Unchanged at $150

Michael Leuchten

Jefferies

CHF110

Hold

-11.86%

Downside

Reiterated

10/27/26

Novartis AG (NOVN) Receives a Hold from Jefferies

Trung Huynh

RBC Capital

CHF120→CHF130

Hold

4.17%

Upside

Reiterated

10/26/26

Novartis AG (NOVN) Receives a Hold from RBC Capital

Kerry Holford

Berenberg Bank

CHF105

Hold

-15.87%

Downside

Reiterated

10/05/26

Novartis AG (NOVN) Receives a Hold from Berenberg Bank

Rajesh Kumar

HSBC

CHF110

Hold

-11.86%

Downside

Upgraded

09/09/26

Novartis upgraded to Hold from Reduce at HSBCNovartis upgraded to Hold from Reduce at HSBC

Unknown Analyst

Bank Vontobel

Not Ranked

Bank Vontobel

CHF130→CHF128

Hold

2.56%

Upside

Reiterated

09/07/26

Bank Vontobel Reaffirms Their Hold Rating on Novartis AG (NOVN)

Shelby Tucker

TD Cowen

CHF138

Hold

10.58%

Upside

Reiterated

07/27/26

Novartis: Solid Fundamentals but Balanced Risk-Reward Justify Hold Rating

Stocks with the Highest Top Analyst Consensus in the General Sector

STDNStandard Nuclear

SKHYSK Hynix

ITGITG Inc. Class A

LIMENeutron Holdings, Inc.

EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novartis AG

3 Months

David EvansKepler Capital

Success Rate

23/31 ratings generated profit

Average Return

+4.10%

Copying David Evans's trades and holding each position for 3 Months would result in 74.19% of your transactions generating a profit, with an average return of +4.10% per trade.

1 Year

David EvansKepler Capital

Success Rate

31/31 ratings generated profit

Average Return

+15.95%

Copying David Evans's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +15.95% per trade.

2 Years

David EvansKepler Capital

Success Rate

31/31 ratings generated profit

Average Return

+30.53%

Copying David Evans's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +30.53% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QLR Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0QLR has received 19 Buy Ratings, 28 Hold Ratings, and 3 Sell Ratings. 0QLR average Analyst price target in the past 3 months is 125.93.

Each month's total comprises the sum of three months' worth of ratings.

0QLR Financial Forecast

0QLR Earnings Forecast

Next quarter’s earnings estimate for 0QLR is CHF1.86 with a range of CHF1.76 to CHF1.92. The previous quarter’s EPS was CHF2.04. 0QLR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year 0QLR has Performed in-line its overall industry.

0QLR Sales Forecast

Next quarter’s sales forecast for 0QLR is CHF12.21B with a range of CHF11.76B to CHF12.64B. The previous quarter’s sales results were CHF11.80B. 0QLR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year 0QLR has Performed in-line its overall industry.

0QLR Stock Forecast FAQ

What is GB:0QLR’s average 12-month price target, according to analysts?

Based on analyst ratings, Novartis AG’s 12-month average price target is 125.93.

What is GB:0QLR’s upside potential, based on the analysts’ average price target?

Novartis AG has 0.90% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novartis AG a Buy, Sell or Hold?

Novartis AG has a consensus rating of Hold, which is based on 4 buy ratings, 9 hold ratings and 1 sell ratings.

What is Novartis AG’s share price target?

The average share price target for Novartis AG is 125.93. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF150.00 ,and the lowest forecast is CHF105.00. The average share price target represents 0.90% Increase from the current price of CHF124.8.

What do analysts say about Novartis AG?

Novartis AG’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of Novartis AG?

To buy shares of GB:0QLR, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Novartis AG (0QLR) Share Forecast & Price Target

0QLR Analyst Ratings

0QLR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novartis AG

0QLR Analyst Recommendation Trends

0QLR Financial Forecast

0QLR Earnings Forecast

0QLR Sales Forecast

0QLR Stock Forecast FAQ

Detailed List of Analyst Forecasts